Literature DB >> 7306225

Decreased capacity to solubilize immune complexes in sera from patients with systemic lupus erythematosus.

M T Aguado, L H Perrin, P A Miescher, P H Lambert.   

Abstract

The capacity to solubilize immune complexes formed in vitro is significantly decreased in patients with systemic lupus erythematosus (SLE). This complement function correlates significantly with serum C3 levels and inversely with the presence of circulating immune complexes. Clinically, patients with a decreased capacity, to solubilize complexes show a worse evolution and an increased incidence of renal involvement. In conclusion, the impaired solubilization capacity, related to low complement activity, which is observed in patients with SLE may favor the persistence of immune complexes in tissues.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7306225     DOI： 10.1002/art.1780241001

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


  10 in total

1.  Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.

Authors:  J A Schifferli; G Steiger; G Hauptmann; P J Spaeth; A G Sjöholm
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

2.  Clearance kinetics and organ uptake of complement-solubilized immune complexes in mice.

Authors:  M T Aguado; M Mannik
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

3.  Complement-mediated solubilization of immune complexes. Solubilization inhibition and complement factor levels in SLE patients.

Authors:  G Baatrup; I Petersen; E Kappelgaard; H H Jepsen; S E Svehag
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

4.  Murine lupus nephritis: effect of azathioprine on glomerular permeability and localization of immunoreactants.

Authors:  T Cavallo; K Graves; N A Granholm
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

5.  A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.

Authors:  F B Waldo; J Forristal; L Beischel; C D West
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

6.  Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera.

Authors:  G Baatrup; I Petersen; J C Jensenius; S E Svehag
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

7.  Complement-mediated delay in immune complex clearance from the blood owing to reduced deposition outside the reticuloendothelial system.

Authors:  T Skogh; O Stendahl
Journal:  Immunology       Date:  1983-05       Impact factor: 7.397

8.  Inhibition of immune complex solubilization by sera of patients with membranoproliferative glomerulonephritis.

Authors:  T R Welch; A Kleesattel; L Beischel
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

9.  Solubilization of intraglomerular deposits of IgG immune complexes by human sera or gamma-globulin in patients with lupus nephritis.

Authors:  Y Tomino; H Sakai; M Takaya; M Miura; T Suga; M Endoh; Y Nomoto
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

10.  Solubilization of immune complex deposits by native 7S IgG molecules in lupus glomerulonephritis--a possible antigen excess effect on rheumatoid factor-IgG complexes.

Authors:  Y Suzuki; T Oite; F Shimizu; K Yamamoto; S Suzuki; M Arakawa
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.